Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

BioNTech is buying into one of the hottest areas of oncology, agreeing to pay $800 million to acquire China-based Biotheus ...

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...